Anti -Lipoprotein Receptor-related Protein 6, Low Density, phosphorylated (S1490) (LRP6, FLJ90062, FLJ90421)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 2; NC_000002.11 (169983619..170219123, complement). Location: 2q31.1

Polyclonal

IgG

Rabbit

Recognizes human LRP-6, when phosphorylated at LRP-6.

Affinity Purified
Purified by immunoaffinity chromatography.

Supplied as a lyophilized powder in PBS, sodium azide, trehalose. Reconstitute with sterile PBS to 200ug/ml.

Lyophilized powder may be stored at -20 degree C. Stable for 12 months at -20 degree C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Reconstituted product is stable for 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Small volumes of anti-LRP2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

LRP6 (Low-density lipoprotein receptor-related protein 6) is a 200-210kD member of the LDLR family of proteins. It is widely expressed, and serves as a coreceptor for both Wnt and parathyroid hormone. In the Wnt system, LRP6 associates with select Fzd multipass receptors; in the PTH system, LRP6 complexes with PTHR1. Mature human LRP6 is a 1594aa type I transmembrane glycoprotein. It contains a 1351aa extracellular region (aa20-1370) plus a 220aa cytoplasmic domain (aa1394-1613). The cytoplasmic domain contains two palmitoylation sites, one ubiquitination residue, and multiple phosphorylation motifs. aa1490 is a key residue that impacts multiple activities. It undergoes both constitutive and receptor activation-induced phosphorylation. At least three enzymes likely act at this site, including PKA (associated with PTHR1), GSK-3 (associated with Fzd) and Cyclin Y/PFTK1 (associated with G2/M of the cell cycle). In general, Ser1490 phosphorylation results in b-catenin stabilization, followed by either gene transcription or b-catenin binding to centrosomes.

Antibodies; Abs to Receptors

Western Blot (WB)

Suitable for use in Western Blot.
Dilution: Western Blot: 1ug/ml

521,958 Da[Similar Products]

low density lipoprotein receptor-related protein 2

low-density lipoprotein receptor-related protein 2; LRP-2; megalin; glycoprotein 330; calcium sensor protein; Heymann nephritis antigen homolog

Low-density lipoprotein receptor-related protein 2

LRP-2; gp330??[Similar Products]

LRP2_HUMAN

The protein encoded by this gene, low density lipoprotein-related protein 2 (LRP2) or megalin, is a multi-ligand endocytic receptor that is expressed in many different tissues but primarily in absorptive epithilial tissues such as the kidney. This glycoprotein has a large amino-terminal extracellular domain, a single transmembrane domain, and a short carboxy-terminal cytoplasmic tail. The extracellular ligand-binding-domains bind diverse macromolecules including albumin, apolipoproteins B and E, and lipoprotein lipase. The LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, vitamin-binding proteins, and hormones. This protein also has a role in cell-signaling; extracellular ligands include parathyroid horomones and the morphogen sonic hedgehog while cytosolic ligands include MAP kinase scaffold proteins and JNK interacting proteins. Recycling of this membrane receptor is regulated by phosphorylation of its cytoplasmic domain. Mutations in this gene cause Donnai-Barrow syndrome (DBS) and facio-oculoacoustico-renal syndrome (FOAR).[provided by RefSeq, Aug 2009]

Function: Acts together with cubilin to mediate HDL endocytosis

By similarity. May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.

Subunit structure: Binds plasminogen, extracellular matrix components, plasminogen activator-plasminogen activator inhibitor type I complex, apolipoprotein E-enriched beta-VLDL, lipoprotein lipase, lactoferrin, CLU/clusterin and calcium. Forms a multimeric complex together with a receptor-associated protein (RAP). Binds to ankyrin-repeat family A protein 2 (ANKRA2). Interacts with LRP2BP. Interacts (via NPXY motif) with DAB2; the interaction is not affected by tyrosine phosphorylation of the NPXY motif. Ref.5 Ref.6 Ref.7 Ref.8

Subcellular location: Membrane; Single-pass type I membrane protein. Membrane ? coated pit.

Tissue specificity: Absorptive epithelia, including renal proximal tubules.

Involvement in disease: Donnai-Barrow syndrome (DBS) [MIM:222448]: Rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g., agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.10

Sequence similarities: Belongs to the LDLR family.Contains 17 EGF-like domains.Contains 36 LDL-receptor class A domains.Contains 37 LDL-receptor class B repeats.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.